COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A randomized 3-arm Phase II study comparing 1) Bendamustine, Rituximab and high dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, high dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in patients

Protocol No
ECOG-EA4181-MCL
Principal Investigator
Timothy Fenske
Phase
II
Summary
This study is being done to answer the following question: Which combination of cancer drugs most effectively treats MCL? 1. bendamustine, rituximab, and high dose cytarabine (BR/CR) 2. bendamustine, rituximab, high dose cytarabine, and acalabrutinib (BR/CR-A) 3. bendamustine, rituximab and acalabrutinib (BR-A)
Description
Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL